Trials to test gene therapy for Parkinson's disease underway.
Washington, Oct 7 (ANI): Scientists at Michigan hospital have launched a trial to test gene transfer therapy that would help restore better mobility in Parkinson's patients who have lost responsiveness to drug therapy.
When brain neurons in brain begin to die, the cells can no longer manufacture the molecule dopamine dopamine (dōp`əmēn), one of the intermediate substances in the biosynthesis of epinephrine and norepinephrine. See catecholamine.
One of the catecholamines, widely distributed in the central nervous system. , a chemical critical for controlling movement.
Most current therapies and research approaches target dopamine to treat motor symptoms associated with Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. .
"The start of this clinical trial provides hope to a Parkinson's disease patient population that has had a long-standing need for better treatment options," said Dr Henry Ford West Bloomfield Hospital neurologist Peter LeWitt, who is internationally known for his research on Parkinson's disease.
In the current study, the researchers are using gene therapy strategy to increase GABA GABA ?.
GABA (gamma-aminobutyric acid)
A neurotransmitter that slows down the activity of nerve cells in the brain. , a brain neurotransmitter that regulates movement.
In Parkinson's disease, GABA is reduced in an area of the brain called the subthalamic nucleus, causing it to be overactive o·ver·ac·tive
Active to an excessive or abnormal degree: an overactive child.
The researchers feel this might be a better way to help advanced Parkinson's disease.
During the clinical trial, the gene therapy product rAAV-GAD will be placed into the subthalamic nucleus by a surgical procedure.
The gene transfer is done through a catheter that is removed shortly after its placement.
As an alternative to this experimental treatment, patients with advanced Parkinson's disease have the option of deep brain stimulation In neurotechnology, deep brain stimulation (DBS) is a surgical treatment involving the implantation of a medical device called a brain pacemaker, which sends electrical impulses to specific parts of the brain. .
This also involves a surgical procedure in which a pacemaker-like device is placed in the brain to help in control of Parkinson's disease symptoms. (ANI)
Copyright 2009 Asian News International The Asian News International (ANI) agency provides multimedia news to China and 50 bureaus in India. It covers virtually all of South Asia since its foundation and presently claims, on its official website, to be the leading South Asia-wide news agency. (ANI) - All Rights Reserved.
Provided by Syndigate.info an Albawaba.com company